<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04298736</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0780</org_study_id>
    <nct_id>NCT04298736</nct_id>
  </id_info>
  <brief_title>Bariatric Surgery vs. Lifestyle Modification for NASH</brief_title>
  <acronym>BeLEANeR</acronym>
  <official_title>Bariatric Surgery vs. Lifestyle Modification: Effects Against Nonalcoholic Steatohepatitis Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized Controlled Trial comparing the effects of Bariatric Surgery vs. Lifestyle
      modification on NASH resolution.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with biopsy-proven NASH will be randomized to either bariatric surgery or lifestyle
      interventions. After 1-year follow-up a liver biopsy will be done to evaluate NASH resolution
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2020</start_date>
  <completion_date type="Anticipated">March 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Blinded pathologist</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>NASH resolution</measure>
    <time_frame>12 months</time_frame>
    <description>NASH resolution evaluated by liver biopsy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Bariatric Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Obese patients, BMI from 30 to 45, with or without type 2 diabetes, submitted to either laparoscopic Roux-en-Y Gastric Bypass or laparoscopic Sleeve Gastrectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lifestyle Modification</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Obese patients, BMI from 30 to 45, with or without type 2 diabetes, submitted to guided diet and physical activity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bariatric Surgery</intervention_name>
    <description>laparoscopic Roux-en-Y gastric bypass or laparoscopic Sleeve Gastrectomy</description>
    <arm_group_label>Bariatric Surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle modification</intervention_name>
    <description>guided low-calorie diet and physical activity.</description>
    <arm_group_label>Lifestyle Modification</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI between 30 and 45

          -  with biopsy-proven NASH

          -  with or without type 2 diabetes

          -  that fit for bariatric surgery.

        Exclusion Criteria:

          -  borderline NASH ou cirrhosis;

          -  alcohol consumption (&gt; 20 g/day for men and &gt; 10 g/day for women, for the last 2
             years);

          -  other hepatic diseases (such as viral hepatitis, autoimmune hepatitis, drug-induced
             hepatic disease, Wilson's disease, hemochromatosis);

          -  HIV infection;

          -  unable to provide informed consent;

          -  previous foregut or bariatric surgery;

          -  malignancy;

          -  patients that unfit for bariatric surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guilherme S Mazzini, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clínicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guilherme S Mazzini, MD, PhD</last_name>
    <phone>+55(51)981364873</phone>
    <email>guimazzini@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guilherme S Mazzini, MD, PhD</last_name>
      <phone>+55(51)981364873</phone>
      <email>guimazzini@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 4, 2020</study_first_submitted>
  <study_first_submitted_qc>March 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2020</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

